Clinical trials: Primary Immunodeficiency Disorders (PIDs)
Primary Immunodeficiency Disorders (PIDs)
Leniolisib for Immune Dysregulation in PIDs
This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib.
- Trial name
- NCT06549114
- Testing
- Leniolisib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Pharming Technologies B.V.
PIDs Linked to PI3K
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
This is an open-label extension (OLE) study to extend treatment to patients with primary immunodeficiency (PID) disorders linked to phosphoinositide 3-kinase delta signaling who participated in a prior study of leniolisib, LE…
- Trial name
- NCT06990529
- Testing
- Leniolisib
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 12 people
- Sponsor
- Pharming Technologies B.V.